因塞特医疗宣布,Minjuvi®(Tafasitamab)与利妥昔单抗及来那度胺联合用于治疗复发或难治性滤泡淋巴瘤获得批准。
因塞特医疗宣布,Minjuvi®(Tafasitamab)与利妥昔单抗及来那度胺联合用于治疗复发或难治性滤泡淋巴瘤获得批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.